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Objective: The aim of this study was to investigate whether anti-Müllerian hormone (AMH) levels could be predict ovarian poor/hyper re-
sponse and IVF cycle outcome.
Methods: Between May 2010 and January 2011, serum AMH levels were evaluated with retrospective analysis. Three hundred seventy infertile 
women undergoing 461 IVF cycles between the ages of 20 and 42 were studied. We defined the poor response as the number of oocytes re-
trieved was equal or less than 3, and the hyper response as more than 25 oocytes retrieved. Serum AMH was measured by commercial enzyme-
linked immunoassay.
Results: The number of oocytes retrieved was more correlated with the serum AMH level (r=0.781, p<0.01) than serum FSH (r=-0.412, p<0.01). 
The cut-off value of serum AMH levels for poor response was 1.05 ng/mL (receiver operating characteristic [ROC] curves/area under the curve 
[AUC], ROCAUC=0.85, sensitivity 74%, specificity 87%). Hyper response cut-off value was 3.55 ng/mL (ROCAUC=0.91, sensitivity 94%, specificity 
81%). When the study group was divided according to the serum AMH levels (low: <1.05 ng/mL, middle: 1.05 ng/mL - 3.55 ng/mL, high: >3.55 
ng/mL), the groups showed no statistical differences in mature oocyte rates (71.6% vs. 76.5% vs. 74.8%) or fertilization rates (76.9% vs. 76.6% vs. 
73.8%), but showed significant differences in clinical pregnancy rates (21.7% vs. 24.1% vs. 40.8%, p=0.017).
Conclusion: The serum AMH level can be used to predict the number of oocytes retrieved in patients, distinguishing poor and high responders. 
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Introduction
In order to do appropriate controlled ovarian hyperstimulation (COH) 
during IVF, the evaluation of the ovarian reserve is necessary [1,2]. 
Assessment of the ovarian reserve via age plays an important role in 
evaluation, but age by itself does not accurately predict the ovarian 
reserve. Traditionally, there are several ovarian reserve tests, includ-
ing those that test for biochemical and ultrasonographic markers. 
Basal FSH, E2 and inhibin B levels are used as biochemical markers. 
But, their values are influenced by the menstrual cycle and have lim-
ited use for predicting poor and high responders. Ultrasonographic 
markers, such as antral follicle count (AFC) and ovarian volumes have 
been shown to be affected by interobserver variation [2-5]. 
Recently, anti-Müllerian hormone (AMH) has been evaluated as a 
potential novel clinical marker of ovarian reserve [6-10]. AMH is a di-
meric glycoprotein belonging to the transforming growth factor-β 
(TGF-β) family. AMH is secreted by sertoli cells in males and inhibits 
the development of the Müllerian ducts in the male fetus [11,12]. In 
females, it is secreted by the granulosa cells in the postpubertal age 
and controls the development of primary follicles by inhibiting fur-
ther recruitment of other follicles during folliculogenesis [13]. Serum 
AMH level is closely related to the AFC, inhibin B, and basal E2. The 
AMH level shows low variability even during changes over the course 
of the menstrual cycle [14,15]. Recent studies have shown that AMH 
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could be a predictor of ovarian reserve and the success rates of IVF 
[16-18]. However, some studies could not find to predict power of 
pregnancy outcomes [19,20].
The aim of this study was therefore to investigate whether AMH 
levels are associated with ovarian response and IVF cycle outcomes.
Methods
1. Study population
Between May 2010 and January 2011, serum AMH levels were eval-
uated with retrospective analysis. The study population included a 
total of 370 infertile women aged between 20 and 42 years who had 
undergone 461 IVF cycles. Exclusion criteria consisted of the follow-
ing factors: 1) Polycystic ovary syndrome, 2) previous history of ovari-
an surgery (including oophorectomy and enucleation of an ovarian 
cyst), 3) body mass index≥30 kg/m², 4) other endocrinological dis-
ease (thyroid disease, diabetes mellitus, Cushing’s syndrome). The 
study group was divided into three groups according to the number 
of oocytes retrieved. Patients with an oocyte count of three or less 
were considered poor responders, and patients with more than four, 
and less than twenty-four as normal responders, and patients with 
more than twenty-five as high responders. We analyzed ovarian re-
sponse and IVF outcomes according to serum AMH levels.
2. Blood sampling and hormones assays
On day 2-3 of a menstrual cycle, blood sample assays of AMH, FSH, 
E2, and LH were obtained by venipuncture. Serum AMH levels were 
measured by enzyme immunoassay using an AMH/MIS EIA kit, which 
was a two-immunological-step sandwich-type assay (Immunotech 
version; Beckman Coulter, Marseille, France). First, the hormone was 
captured by a monoclonal antibody bound to the microtiter plate. 
Then, another monoclonal antibody with streptavidin-peroxidase 
bound to the solid phase antibody-antigen complex. After incuba-
tion, the antibody-antigen complex was detected by the addition of 
a chromogenic substrate. The serum AMH concentration was repre-
sented by the intensity of the coloration in the blood samples and 
then converted to ng/mL (conversion factor to pmol/L=ng/mL× 
7.14). The measurement range of the assay was from 0.14 ng/mL to 
21 ng/mL. Serum AMH values below the reported clinical level of 
measurement (0.14 ng/mL) were treated as a zero value for analysis. 
The intra- and interassay coefficients of variation were 12.3% and 14. 
2%, respectively.
Serum levels of FSH, LH, and E2 were determined using a Modular 
E170. More blood samples of E2 and LH were collected on the day of 
administration of hCG and measured in the same way.
3. Controlled ovarian hyperstimulation
On day 2-3 of the menstrual cycle, pelvic cavity abnormalities in-
cluding ovarian tumors were checked for through a pelvic ultrasound. 
The patients underwent IVF treatment using a long down-regulation 
or short flare-up protocol with GnRH agonist or a GnRH antagonist 
protocol. In the GnRH agonist protocol, pituitary suppression was ini-
tiated with buserelin acetate (Superfact®, Sanofi-Aventis, Frankfrut, 
Germany) 0.5 mg or leuprolide acetate (Lucrin®, Abbot Lab, Chicago, 
IL, USA) 0.1 mg, subcutaneous injection, from day 3 of the cycle to 
the day of hCG administration. GnRH antagonist, a daily 0.25 mg sub-
cutaneous injection of (Cetrorelix acetate, Cetrotide®, Serono, Darm-
stadt, Switzerland or ganirelix acetate (Orgalutran®, Schering-plough, 
Whitehouse Station, NJ, USA) was administered when the follicles 
were more than 12 mm in diameter or serum E2 concentrations were 
greater than 200 pg/mL. The dosage of gonadotrophin was deter-
mined by the age of the patient and the ovarian response of the pre-
vious cycle. The stimulation was monitored through follicle size and 
serum E2 levels. When a dominant follicle ≥18 mm in diameter was 
detected by ultrasonography, 250 μg choriogonadotropin-alfa (Ovi-
drel®, Serono, Roma, Italy) was administered. Transvaginal ultrasound-
guided oocyte retrieval was performed 36 hours after choriogonado-
tropin-alfa injection. We performed IVF or ICSI with either ejaculated 
sperm or surgically retrieved sperm. The embryos were transferred 
into the uterine cavity on day 3-5 after oocyte retrieval. Pregnancy 
was determined by a serial serum β-hCG level of >5 mIL/mL at 12 
days after the oocyte retrieval. Clinical pregnancy was defined as the 
presence of a intrauterine gestational sac by ultrasonography at ap-
proximately 5 weeks of pregnancy.
4. Statistical analysis
All analyses were performed using SPSS ver. 12.0 (SPSS Inc., Chica-
go, IL, USA). One-way analysis of variance and receiver operating 
characteristic (ROC) curve analysis were used for statistical analysis. 
Each variable is presented as mean±SD. A p<0.05 was considered 
statistically significant.
Results
When groups were divided according to the number of oocytes re-
trieved, the age of poor, normal and high responders showed decre-
asing pattern in each group (37.6±3.3, 35.1±3.8, 33.1±3.0; p<0.05). 
The AMH level showed increasing pattern in each group (0.9±0.7, 
2.9±2.2, 7.6±2.9; p<0.001). The basal FSH level among the three 
groups shows significant differences (13.9±7.7, 9.2±4.1, 6.3±1.8; 
p<0.01) (Table 1). The number of oocytes retrieved was more corre-
lated with the serum AMH level (r=0.781, p<0.01) than serum FSH 
(r=-0.412, p<0.01) (Figure 1).www.eCERM.org
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We analyzed the cut-off value of AMH by using the ROC curve to 
predict poor response and hyper response by the number of oocytes 
retrieved. The cut-off value of serum AMH levels for poor response 
was 1.05 ng/mL (ROC curves/area under the curve [AUC], ROCAUC= 
0.85; sensitivity 74%, specificity 87%) (Figure 2). The cut-off value of 
serum AMH levels for hyper response was 3.55 ng/mL (ROCAUC=0.91, 
sensitivity 94%, specificity 81%) (Figure 3). 
When the study group was divided according to serum AMH levels 
(low: AMH<1.05 ng/mL, middle: 1.05 ng/mL≤AMH≤3.55 ng/mL, 
high: AMH>3.55 ng/mL), they showed no statistical difference in 
mature oocyte rates (71.6% vs. 76.5% vs. 74.8%) or fertilization rates 
(76.9% vs. 76.6% vs. 73.8 %) (Table 2). Statistical differences were 
found in the number of oocytes retrieved (2.5±2.2 vs. 7.6±4.9 vs. 
19.6±9.7; p<0.001) and age (37.3±3.6 vs. 35.7±3.7 vs. 33.7±3.6; 
p<0.001) and clinical pregnancy rates (21.7% vs. 24.1% vs. 40.8%; 
p=0.017) (Table 2).
Discussion
Decreased ovarian reserve in advanced-aged women reduces the 
Table 1. Basal characteristics of the study population according to 
ovarian response
Ovarian response Poor  Normal  Hyper
No. of cycles (n) 149 280 32
No. of patients 101 239 30
Age (yr) 37.6±3.3
a 35.1±3.8 33.1±3.0
a
AMH (ng/mL) 0.9±0.7
a 2.9±2.2 7.6±2.9
a
Body mass index (kg/m
2) 20.6±2.9 21.2±2.8 20.1±2.1
a
Basal FSH (mIU/mL) 13.9±7.7
a 9.2±4.1 6.3±1.8
a
Basal LH (mIU/mL) 5.4±3.2 5.1±2.6 5.1±2.5
Stimulation duration (day) 9.1±2.6
a 9.8±1.7 9.8±1.3
To tal used dosage of  
gonadotropin (IU)
2,197±1269
a 2,821±874 2,470±725
a
Values are presented as mean±SD.
AMH, anti-Müllerian hormone. 
ap<0.05: compared to normal responder.
Figure 1. Anti-Müllerian hormone (AMH), FSH and number of oocytes retrieved (A). AMH is strongly correlated with the number of oocytes re-
trieved (r=0.781) (p<0.01). (B) FSH is correlated negatively with the number of oocytes retrieved (r=-0.412) (p<0.01).
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Figure 2.  Cut-off value of serum anti-Müllerian hormone (AMH) for 
poor responders. Cut-off AMH value=1.05 ng/mL (receiver operat-
ing characteristic [ROC] curves/area under the curve [AUC], RO-
CAUC=0.85, sensitivity 74%, specificity 87%).
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possibility of pregnancy. AMH has recently received attention as an 
indicator of women’s fertility. This hormone appears in the 36th week 
of gestation, decreases continuously through puberty, and becomes 
undetectable when menopause occurs [21,22].
In IVF treatment, age, basal FSH, AFC, and inhibin B are useful as in-
dicators in assessing basal ovarian reserve, but these indicators have 
several limitations. 
FSH level predicts poor responders [23]. However, in a meta-analy-
sis, it has been concluded that basal FSH is not a useful predictor of 
IVF outcome [24], possibly because of intercycle variability [25]. AMH 
has little intercycle variability in comparison FSH, and AMH has been 
known to correlate with the AFC, the number of oocytes retrieved that 
reflect ovarian reserve. 
In this study, AMH level has closely correlated with the number of 
oocytes retrieved. 
A prospective study comparing serum AMH with AFC in 130 COH 
cycles showed that the two markers performed similarly in the pre-
diction of the number of oocytes retrieved [26]. Bancsi et al. [27] de-
monstrated that the AFC provides better prognostic information on 
the occurrence of poor response during hormone stimulation for IVF 
than does the patient’s chronological age and the currently used en-
docrine markers. However, conducting an antral follicle count has 
limited intraobserver and interobserver reproducibility. Considering 
these points, AMH appears to be the best predictor of ovarian reserve. 
La Marca et al. [28] defined the cut-off value of serum AMH level as 
0.5 ng/mL for the prediction of poor response (sensitivity 85.0%, spec-
ificity 82.3%). Seifer et al. [29] defined the mean serum AMH level as 
1.0±0.4 ng/mL for the prediction of the group with ≤6 oocytes re-
trieved .
In addition, Eldar-Geva et al. [30] considered AMH level not only as 
a quantitative indicator of the number of oocytes retrieved but also 
as a qualitative indicator of oocyte quality, fertilization rate, and clini-
cal pregnancy rate. Though this relationship between AMH level and 
oocyte quality, fertilization rate, and clinical pregnancy rate has been 
studied, no distinct correlation among them has been revealed. 
Buyuk et al. [31] found that the clinical pregnancy rate was higher 
among women with a random serum AMH>0.6 ng/mL (28% vs. 
14%); however, the difference was not statistically significant. Silber-
stein et al. [32] reported good embryo quality when AMH level >2.7 
ng/mL on the day of hCG administration. Ebner et al. [33] reported 
that on day 3 of the menstrual cycle, the AMH level was associated 
with the quality of oocytes. Wang et al. [34] found that AMH has lim-
ited predictive value for IVF outcomes in the two extremes of female 
reproduction. Women between 34 and 41 years old with higher se-
rum AMH concentrations are associated with significantly greater 
Figure 3.  Cut-off value of serum anti-Müllerian hormone (AMH) for 
high responders. Cut-off AMH value=3.55 ng/mL (receiver operat-
ing characteristic [ROC] curves/area under the curve [AUC], RO-
CAUC=0.91, sensitivity 94%, specificity 81%).
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Table 2. IVF outcome according to the serum anti-Müllerian hormone (AMH) level
Serum AMH levels (ng/mL) Low (<1.05) Middle (1.05-3.55) High (>3.55) p-value
Cycles (n) 152 196 113
Age (yr) 37.3±3.6
a  35.7±3.7  33.7±3.6
a  <0.001
Number of oocytes retrieved   2.5±2.2
a    7.6±4.9 19.6±9.7
a <0.001
Mature oocytes rate (%) 71.6  76.5 74.8 NS
Fertilization rate (%)  76.9 76.6 73.8 NS
Clinical pregnancy rate (%) 20/92 (21.7) 41/170 (24.1)   40/98 (40.8)
a 0.017
Miscarriage rate (%) 7/92 (7.6) 7/170 (4.1) 7/98 (7.1) NS
Biochemical pregnancy rate (%) 8/92 (8.7) 22/170 (12.9) 9/98 (9.2) NS
Moderate OHSS (n) 0 0 8 NS
Values are presented as mean±SD.
NS, not significant; OHSS, ovarian hyperstimulation syndrome.
a p-value: compared to middle AMH group. www.eCERM.org
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chances of pregnancy (p<0.01). However, Smeenk et al. [19] found 
that the AMH level on day 3 of the menstrual cycle was not related to 
the quality of oocytes and pregnancy rate.
In this study, the mature oocyte rate and the fertilization rate did not 
show any significant differences according to the AMH level. Qualita-
tive criteria such as the morphology of the retrieved oocytes and em-
bryo should therefore be considered in an expanded study.
The main limitations of this study are its retrospective design and 
the absence of antral follicle counts.
In conclusion, serum AMH level is more useful than the basal FSH 
level that is currently being used. This study we are able to inform 
cut-off values to predict poor response and hyper response during 
IVF treatment through the serum AMH level. This cut-off value may 
be supported by further study. 
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